| scholarly article | Q13442814 |
| P2093 | author name string | Qing Guo | |
| Anhua Wu | |||
| Ling Chen | |||
| Chen Zhu | |||
| Xiaoyan Xu | |||
| Wen Cheng | |||
| Tianqi Liu | |||
| Shuai Shen | |||
| Cunyi Zou | |||
| Gefei Guan | |||
| Zhiguo Lin | |||
| Zihao Yan | |||
| P2860 | cites work | Next generation of immune checkpoint therapy in cancer: new developments and challenges. | Q52653710 |
| Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. | Q53922343 | ||
| Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. | Q55457206 | ||
| IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas. | Q55463659 | ||
| Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 | Q78804319 | ||
| Signalling pathways identified in salivary glands from primary Sjögren's syndrome patients reveal enhanced adipose tissue development | Q87961247 | ||
| Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma | Q90935191 | ||
| Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions | Q28593445 | ||
| TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy | Q30399437 | ||
| Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. | Q30513468 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth | Q34457728 | ||
| Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells | Q35003509 | ||
| Phosphorylated SATB1 is associated with the progression and prognosis of glioma | Q35029678 | ||
| HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation | Q35203538 | ||
| Development of novel targeted therapies in the treatment of malignant glioma | Q35770177 | ||
| Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. | Q35889643 | ||
| Mechanisms of suppression by suppressor T cells | Q36078047 | ||
| Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 | ||
| Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease | Q36672085 | ||
| Roles of CD48 in regulating immunity and tolerance | Q36883146 | ||
| Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome | Q36903959 | ||
| S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages | Q37051646 | ||
| Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects | Q37190486 | ||
| T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. | Q37208738 | ||
| Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression | Q37356734 | ||
| Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma | Q37477267 | ||
| Tumor Purity As an Underlying Key Factor in Glioma | Q38438749 | ||
| Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma | Q38438906 | ||
| Immunotherapy comes of age: Immune aging & checkpoint inhibitors | Q38949503 | ||
| Improving vaccine efficacy against malignant glioma | Q38953024 | ||
| Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma | Q39160992 | ||
| Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses | Q39328886 | ||
| Anti-CD48 Monoclonal Antibody Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of Pathogenic CD4+ T Cells | Q39434959 | ||
| Engagement of SLAMF2/CD48 prolongs the time frame of effective T cell activation by supporting mature dendritic cell survival | Q39506089 | ||
| Bioinformatic profiling identifies an immune-related risk signature for glioblastoma | Q39736294 | ||
| Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade | Q40082476 | ||
| Mutant IDH1 regulates the tumor-associated immune system in gliomas | Q42259199 | ||
| Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples | Q42777737 | ||
| Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. | Q43290383 | ||
| Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. | Q44837814 | ||
| Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy | Q45864012 | ||
| Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy | Q46096916 | ||
| PD-1 related transcriptome profile and clinical outcome in diffuse gliomas | Q47199921 | ||
| NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. | Q47310069 | ||
| The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging | Q48133211 | ||
| Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. | Q48425815 | ||
| Current state and future prospects of immunotherapy for glioma | Q50109459 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ggplot2 | Q326489 |
| P304 | page(s) | 4181-4193 | |
| P577 | publication date | 2019-05-28 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | CD48 is a key molecule of immunomodulation affecting prognosis in glioma | |
| P478 | volume | 12 |
| Q89877520 | AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats | cites work | P2860 |
Search more.